{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,14]],"date-time":"2026-07-14T16:05:40Z","timestamp":1784045140027,"version":"3.55.0"},"reference-count":57,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T00:00:00Z","timestamp":1733356800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat. Biomed. Eng"],"DOI":"10.1038\/s41551-024-01289-1","type":"journal-article","created":{"date-parts":[[2024,12,5]],"date-time":"2024-12-05T05:02:26Z","timestamp":1733374946000},"page":"1715-1729","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":9,"title":["In vivo affinity maturation of the CD4 domains of an HIV-1-entry inhibitor"],"prefix":"10.1038","volume":"8","author":[{"given":"Andi","family":"Pan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Charles C.","family":"Bailey","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5119-2239","authenticated-orcid":false,"given":"Tianling","family":"Ou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jinge","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tonia","family":"Aristotelous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xin","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Baodan","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gogce","family":"Crynen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nickolas","family":"Skamangas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naomi","family":"Bronkema","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mai H.","family":"Tran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Huihui","family":"Mou","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xia","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael D.","family":"Alpert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0087-2784","authenticated-orcid":false,"given":"Yiming","family":"Yin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2990-5319","authenticated-orcid":false,"given":"Michael","family":"Farzan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenhui","family":"He","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,12,5]]},"reference":[{"key":"1289_CR1","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38039-x","volume":"14","author":"SB Ebrahimi","year":"2023","unstructured":"Ebrahimi, S. B. & Samanta, D. Engineering protein-based therapeutics through structural and chemical design. Nat. Commun. 14, 2411 (2023).","journal-title":"Nat. Commun."},{"key":"1289_CR2","doi-asserted-by":"publisher","first-page":"14336","DOI":"10.1073\/pnas.0805942105","volume":"105","author":"RR Beerli","year":"2008","unstructured":"Beerli, R. R. et al. Isolation of human monoclonal antibodies by mammalian cell display. Proc. Natl Acad. Sci. USA 105, 14336\u201314341 (2008).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1289_CR3","doi-asserted-by":"publisher","first-page":"553","DOI":"10.1038\/nbt0697-553","volume":"15","author":"E Boder","year":"1997","unstructured":"Boder, E. & Wittrup, D. Yeast surface display for screening combinatorial polypeptide libraries. Nat. Biotechnol. 15, 553\u2013557 (1997).","journal-title":"Nat. Biotechnol."},{"key":"1289_CR4","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1126\/science.4001944","volume":"228","author":"GP Smith","year":"1985","unstructured":"Smith, G. P. Filamentous fusion phage: novel expression vectors that display cloned antigens on the virion surface. Science 228, 1315\u20131317 (1985).","journal-title":"Science"},{"key":"1289_CR5","doi-asserted-by":"publisher","DOI":"10.1073\/pnas.2106203118","volume":"118","author":"Y Yin","year":"2021","unstructured":"Yin, Y. et al. In vitro affinity maturation of broader and more-potent variants of the HIV-1\u2013neutralizing antibody CAP256-VRC26.25. Proc. Natl Acad. Sci. USA 118, e2106203118 (2021).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1289_CR6","doi-asserted-by":"publisher","first-page":"469","DOI":"10.3389\/fbioe.2019.00469","volume":"7","author":"X Ren","year":"2019","unstructured":"Ren, X., Zhao, M., Lash, B., Martino, M. M. & Julier, Z. Growth factor engineering strategies for regenerative medicine applications. Front. Bioeng. Biotechnol. 7, 469 (2019).","journal-title":"Front. Bioeng. Biotechnol."},{"key":"1289_CR7","doi-asserted-by":"publisher","first-page":"1906","DOI":"10.1126\/science.1111781","volume":"308","author":"BF Haynes","year":"2005","unstructured":"Haynes, B. F. et al. Cardiolipin polyspecific autoreactivity in two broadly neutralizing HIV-1 antibodies. Science 308, 1906\u20131908 (2005).","journal-title":"Science"},{"key":"1289_CR8","doi-asserted-by":"publisher","first-page":"1249","DOI":"10.1128\/JVI.02664-13","volume":"88","author":"J Chen","year":"2014","unstructured":"Chen, J. et al. Mechanism of HIV-1 neutralization by antibodies targeting a membrane-proximal region of gp41. J. Virol. 88, 1249\u20131258 (2014).","journal-title":"J. Virol."},{"key":"1289_CR9","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-023-38525-2","volume":"14","author":"DP Arnold","year":"2023","unstructured":"Arnold, D. P., Xu, Y. & Takatori, S. C. Antibody binding reports spatial heterogeneities in cell membrane organization. Nat. Commun. 14, 2884 (2023).","journal-title":"Nat. Commun."},{"key":"1289_CR10","doi-asserted-by":"publisher","first-page":"376","DOI":"10.4161\/mabs.3.4.15786","volume":"3","author":"D Bumbaca","year":"2011","unstructured":"Bumbaca, D. et al. Highly specific off-target binding identified and eliminated during the humanization of an antibody against FGF receptor 4. mAbs 3, 376\u2013386 (2011).","journal-title":"mAbs"},{"key":"1289_CR11","doi-asserted-by":"publisher","first-page":"335","DOI":"10.4161\/mabs.2.3.11850","volume":"2","author":"Y Vugmeyster","year":"2010","unstructured":"Vugmeyster, Y. et al. In vitro potency, pharmacokinetic profiles and pharmacological activity of optimized anti-IL-21R antibodies in a mouse model of lupus. mAbs 2, 335\u2013346 (2010).","journal-title":"mAbs"},{"key":"1289_CR12","doi-asserted-by":"publisher","first-page":"652","DOI":"10.1016\/j.jmb.2007.02.024","volume":"368","author":"H Wu","year":"2007","unstructured":"Wu, H. et al. Development of motavizumab, an ultra-potent antibody for the prevention of respiratory syncytial virus infection in the upper and lower respiratory tract. J. Mol. Biol. 368, 652\u2013665 (2007).","journal-title":"J. Mol. Biol."},{"key":"1289_CR13","doi-asserted-by":"publisher","first-page":"413","DOI":"10.1146\/annurev-immunol-120419-022408","volume":"40","author":"GD Victora","year":"2022","unstructured":"Victora, G. D. & Nussenzweig, M. C. Germinal centers. Annu. Rev. Immunol. 40, 413\u2013442 (2022).","journal-title":"Annu. Rev. Immunol."},{"key":"1289_CR14","doi-asserted-by":"publisher","first-page":"296","DOI":"10.1038\/ni.3095","volume":"16","author":"LJ McHeyzer-Williams","year":"2015","unstructured":"McHeyzer-Williams, L. J., Milpied, P. J., Okitsu, S. L. & McHeyzer-Williams, M. G. Class-switched memory B cells remodel BCRs within secondary germinal centers. Nat. Immunol. 16, 296\u2013305 (2015).","journal-title":"Nat. Immunol."},{"key":"1289_CR15","first-page":"5638","volume":"5","author":"H Wardemann","year":"2003","unstructured":"Wardemann, H. et al. Predominant autoantibody production by early human B cell precursors. Science 5, 5638 (2003).","journal-title":"Science"},{"key":"1289_CR16","doi-asserted-by":"publisher","first-page":"14","DOI":"10.1038\/ni.1794","volume":"11","author":"H von Boehmer","year":"2010","unstructured":"von Boehmer, H. & Melchers, F. Checkpoints in lymphocyte development and autoimmune disease. Nat. Immunol. 11, 14\u201320 (2010).","journal-title":"Nat. Immunol."},{"key":"1289_CR17","doi-asserted-by":"publisher","first-page":"4743","DOI":"10.1073\/pnas.1803457115","volume":"115","author":"P Dosenovic","year":"2018","unstructured":"Dosenovic, P. et al. Anti-HIV-1 B cell responses are dependent on B cell precursor frequency and antigen-binding affinity. Proc. Natl Acad. Sci. USA 115, 4743\u20134748 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1289_CR18","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1111\/imr.13039","volume":"306","author":"J Pae","year":"2022","unstructured":"Pae, J., Jacobsen, J. T. & Victora, G. D. Imaging the different timescales of germinal center selection. Immunol. Rev. 306, 234\u2013243 (2022).","journal-title":"Immunol. Rev."},{"key":"1289_CR19","doi-asserted-by":"publisher","first-page":"2408","DOI":"10.1016\/j.immuni.2023.07.003","volume":"56","author":"W He","year":"2023","unstructured":"He, W. et al. Heavy-chain CDR3-engineered B cells facilitate in vivo evaluation of HIV-1 vaccine candidates. Immunity 56, 2408\u20132424.e6 (2023).","journal-title":"Immunity"},{"key":"1289_CR20","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1038\/s41551-024-01179-6","volume":"8","author":"Y Yin","year":"2024","unstructured":"Yin, Y. et al. In vivo affinity maturation of mouse B cells reprogrammed to express human antibodies. Nat. Biomed. Eng. 8, 361\u2013379 (2024).","journal-title":"Nat. Biomed. Eng."},{"key":"1289_CR21","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41551-024-01184-9","volume":"8","author":"Y Yin","year":"2024","unstructured":"Yin, Y. & Farzan, M. Affinity maturation of CRISPR-engineered B cell receptors in vivo. Nat. Biomed. Eng. 8, 341\u2013342 (2024).","journal-title":"Nat. Biomed. Eng."},{"key":"1289_CR22","doi-asserted-by":"publisher","first-page":"660757","DOI":"10.3389\/fphar.2021.660757","volume":"12","author":"C Junren","year":"2021","unstructured":"Junren, C. et al. Pharmacological activities and mechanisms of hirudin and its derivatives \u2013 a review. Front. Pharmacol. 12, 660757 (2021).","journal-title":"Front. Pharmacol."},{"key":"1289_CR23","doi-asserted-by":"publisher","DOI":"10.1186\/s13613-023-01109-w","volume":"13","author":"T Daix","year":"2023","unstructured":"Daix, T. et al. Intravenously administered interleukin-7 to reverse lymphopenia in patients with septic shock: a double-blind, randomized, placebo-controlled trial. Ann. Intensive Care 13, 17 (2023).","journal-title":"Ann. Intensive Care"},{"key":"1289_CR24","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-022-30860-0","volume":"13","author":"MY Kim","year":"2022","unstructured":"Kim, M. Y. et al. A long-acting interleukin-7, rhIL-7-hyFc, enhances CAR T cell expansion, persistence, and anti-tumor activity. Nat. Commun. 13, 3296 (2022).","journal-title":"Nat. Commun."},{"key":"1289_CR25","doi-asserted-by":"publisher","first-page":"1761","DOI":"10.1182\/blood-2015-09-669234","volume":"127","author":"E Santagostino","year":"2016","unstructured":"Santagostino, E. et al. Long-acting recombinant coagulation factor IX albumin fusion protein (rIX-FP) in hemophilia B: results of a phase 3 trial. Blood 127, 1761\u20131769 (2016).","journal-title":"Blood"},{"key":"1289_CR26","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1016\/j.immuni.2006.03.001","volume":"24","author":"JA Bluestone","year":"2006","unstructured":"Bluestone, J. A., St Clair, E. W. & Turka, L. A. CTLA4Ig: bridging the basic immunology with clinical application. Immunity 24, 233\u2013238 (2006).","journal-title":"Immunity"},{"key":"1289_CR27","doi-asserted-by":"publisher","first-page":"3296","DOI":"10.3389\/fimmu.2022.926648","volume":"13","author":"M Iglesias","year":"2022","unstructured":"Iglesias, M., Brennan, D. C., Larsen, C. P. & Raimondi, G. Targeting inflammation and immune activation to improve CTLA4-Ig-based modulation of transplant rejection. Front. Immunol. 13, 3296 (2022).","journal-title":"Front. Immunol."},{"key":"1289_CR28","doi-asserted-by":"publisher","DOI":"10.1038\/s41598-023-40925-9","volume":"13","author":"M Inoue","year":"2023","unstructured":"Inoue, M. et al. Bivalent structure of a TNFR2-selective and agonistic TNF-\u03b1 mutein Fc-fusion protein enhances the expansion activity of regulatory T cells. Sci. Rep. 13, 13762 (2023).","journal-title":"Sci. Rep."},{"key":"1289_CR29","doi-asserted-by":"publisher","first-page":"401","DOI":"10.3389\/fcell.2020.00401","volume":"8","author":"R Fischer","year":"2020","unstructured":"Fischer, R., Kontermann, R. E. & Pfizenmaier, K. Selective targeting of TNF receptors as a novel therapeutic approach. Front. Cell Dev. Biol. 8, 401 (2020).","journal-title":"Front. Cell Dev. Biol."},{"key":"1289_CR30","doi-asserted-by":"publisher","first-page":"1774","DOI":"10.1086\/317622","volume":"182","author":"TW Shearer","year":"2000","unstructured":"Shearer, T. W. et al. Recombinant CD4\u2010IgG2 in human immunodeficiency virus type 1-infected children: phase 1\/2 study. J. Infect. Dis. 182, 1774\u20131779 (2000).","journal-title":"J. Infect. Dis."},{"key":"1289_CR31","doi-asserted-by":"publisher","first-page":"eaau5409","DOI":"10.1126\/scitranslmed.aau5409","volume":"11","author":"MR Gardner","year":"2019","unstructured":"Gardner, M. R. et al. AAV-delivered eCD4-Ig protects rhesus macaques from high-dose SIVmac239 challenges. Sci. Transl. Med. 11, eaau5409 (2019).","journal-title":"Sci. Transl. Med."},{"key":"1289_CR32","doi-asserted-by":"publisher","first-page":"747","DOI":"10.1016\/j.jaci.2006.10.045","volume":"119","author":"CV Fletcher","year":"2007","unstructured":"Fletcher, C. V. et al. Nonlinear pharmacokinetics of high-dose recombinant fusion protein CD4-IgG2 (PRO 542) observed in HIV-1\u2013infected children. J. Allergy Clin. Immunol. 119, 747\u2013750 (2007).","journal-title":"J. Allergy Clin. Immunol."},{"key":"1289_CR33","doi-asserted-by":"publisher","first-page":"326","DOI":"10.1086\/315698","volume":"182","author":"MJ Jacobson","year":"2000","unstructured":"Jacobson, M. J. et al. Single\u2010dose safety, pharmacology, and antiviral activity of the human immunodeficiency virus (HIV) type 1 entry inhibitor PRO 542 in HIV\u2010infected adults. J. Infect. Dis. 182, 326\u2013329 (2000).","journal-title":"J. Infect. Dis."},{"key":"1289_CR34","unstructured":"Gardner, M. & Farzan, M. Cd4 muteins and methods of using the same. US patent 20230159616-A1 (2023)."},{"key":"1289_CR35","doi-asserted-by":"publisher","first-page":"e02011","DOI":"10.1128\/JVI.02011-17","volume":"92","author":"I Fetzer","year":"2018","unstructured":"Fetzer, I. et al. eCD4-Ig variants that more potently neutralize HIV-1. J. Virol. 92, e02011\u2013e02017 (2018).","journal-title":"J. Virol."},{"key":"1289_CR36","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1016\/j.ymthe.2021.10.027","volume":"30","author":"T Ou","year":"2022","unstructured":"Ou, T. et al. Reprogramming of the heavy-chain CDR3 regions of a human antibody repertoire. Mol. Ther. 30, 184\u2013197 (2022).","journal-title":"Mol. Ther."},{"key":"1289_CR37","doi-asserted-by":"publisher","first-page":"4221","DOI":"10.4049\/jimmunol.176.7.4221","volume":"176","author":"CM Johnston","year":"2006","unstructured":"Johnston, C. M., Wood, A. L., Bolland, D. J. & Corcoran, A. E. Complete sequence assembly and characterization of the C57BL\/6 mouse Ig heavy chain V region. J. Immunol. 176, 4221\u20134234 (2006).","journal-title":"J. Immunol."},{"key":"1289_CR38","doi-asserted-by":"publisher","first-page":"7846","DOI":"10.1073\/pnas.1608649113","volume":"113","author":"SG Lin","year":"2016","unstructured":"Lin, S. G. et al. Highly sensitive and unbiased approach for elucidating antibody repertoires. Proc. Natl Acad. Sci. USA 113, 7846\u20137851 (2016).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1289_CR39","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.immuni.2017.11.023","volume":"48","author":"RK Abbott","year":"2018","unstructured":"Abbott, R. K. et al. Precursor frequency and affinity determine B cell competitive fitness in germinal centers, tested with germline-targeting HIV vaccine immunogens. Immunity 48, 133\u2013146.e6 (2018).","journal-title":"Immunity"},{"key":"1289_CR40","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1038\/nature14264","volume":"519","author":"MR Gardner","year":"2015","unstructured":"Gardner, M. R. et al. AAV-expressed eCD4-Ig provides durable protection from multiple SHIV challenges. Nature 519, 87\u201391 (2015).","journal-title":"Nature"},{"key":"1289_CR41","doi-asserted-by":"publisher","first-page":"294","DOI":"10.1097\/COH.0000000000000367","volume":"12","author":"MR Gardner","year":"2017","unstructured":"Gardner, M. R. & Farzan, M. Engineering antibody-like inhibitors to prevent and treat HIV-1 infection. Curr. Opin. HIV AIDS 12, 294\u2013301 (2017).","journal-title":"Curr. Opin. HIV AIDS"},{"key":"1289_CR42","doi-asserted-by":"publisher","first-page":"3382","DOI":"10.4049\/jimmunol.172.6.3382","volume":"172","author":"IB Rogozin","year":"2004","unstructured":"Rogozin, I. B. & Diaz, M. Cutting edge: DGYW\/WRCH is a better predictor of mutability at G:C bases in Ig hypermutation than the widely accepted RGYW\/WRCY motif and probably reflects a two-step activation-induced cytidine deaminase-triggered process. J. Immunol. 172, 3382\u20133384 (2004).","journal-title":"J. Immunol."},{"key":"1289_CR43","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.cell.2022.11.031","volume":"186","author":"RVH de Carvalho","year":"2023","unstructured":"de Carvalho, R. V. H. et al. Clonal replacement sustains long-lived germinal centers primed by respiratory viruses. Cell 186, 131\u2013146.e13 (2023).","journal-title":"Cell"},{"key":"1289_CR44","doi-asserted-by":"publisher","first-page":"147","DOI":"10.1016\/j.cell.2022.11.032","volume":"186","author":"T H\u00e4ggl\u00f6f","year":"2023","unstructured":"H\u00e4ggl\u00f6f, T. et al. Continuous germinal center invasion contributes to the diversity of the immune response. Cell 186, 147\u2013161.e15 (2023).","journal-title":"Cell"},{"key":"1289_CR45","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1006\/viro.1997.8651","volume":"234","author":"R Krykbaev","year":"1997","unstructured":"Krykbaev, R., McKeating, J. & Jones, I. Mutant CD4 molecules with improved binding to HIV envelope protein gp120 selected by phage display. Virology 234, 196\u2013202 (1997).","journal-title":"Virology"},{"key":"1289_CR46","doi-asserted-by":"publisher","first-page":"9361","DOI":"10.1016\/S0021-9258(19)50432-X","volume":"267","author":"P Tsui","year":"1992","unstructured":"Tsui, P., Sweet, R. W., Sathe, G. & Rosenberg, M. An efficient phage plaque screen for the random mutational analysis of the interaction of HIV-1 gp120 with human CD4. J. Biol. Chem. 267, 9361\u20139367 (1992).","journal-title":"J. Biol. Chem."},{"key":"1289_CR47","doi-asserted-by":"publisher","first-page":"2489","DOI":"10.1128\/JVI.02853-13","volume":"88","author":"A deCamp","year":"2014","unstructured":"deCamp, A. et al. Global panel of HIV-1 Env reference strains for standardized assessments of vaccine-elicited neutralizing antibodies. J. Virol. 88, 2489\u20132507 (2014).","journal-title":"J. Virol."},{"key":"1289_CR48","doi-asserted-by":"publisher","first-page":"569","DOI":"10.1016\/j.molcel.2009.04.028","volume":"34","author":"MJ Feige","year":"2009","unstructured":"Feige, M. J. et al. An unfolded CH1 domain controls the assembly and secretion of IgG antibodies. Mol. Cell 34, 569\u2013579 (2009).","journal-title":"Mol. Cell"},{"key":"1289_CR49","doi-asserted-by":"publisher","first-page":"e1006786","DOI":"10.1371\/journal.ppat.1006786","volume":"13","author":"ME Davis-Gardner","year":"2017","unstructured":"Davis-Gardner, M. E., Gardner, M. R., Alfant, B. & Farzan, M. eCD4-Ig promotes ADCC activity of sera from HIV-1-infected patients. PLoS Pathog. 13, e1006786 (2017).","journal-title":"PLoS Pathog."},{"key":"1289_CR50","doi-asserted-by":"publisher","first-page":"e00443-","DOI":"10.1128\/JVI.00443-19","volume":"93","author":"CH Fellinger","year":"2019","unstructured":"Fellinger, C. H. et al. eCD4-Ig limits HIV-1 escape more effectively than CD4-Ig or a broadly neutralizing antibody. J. Virol. 93, e00443-19 (2019).","journal-title":"J. Virol."},{"key":"1289_CR51","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19650-8","volume":"11","author":"D Huang","year":"2020","unstructured":"Huang, D. et al. Vaccine elicitation of HIV broadly neutralizing antibodies from engineered B cells. Nat. Commun. 11, 5850 (2020).","journal-title":"Nat. Commun."},{"key":"1289_CR52","doi-asserted-by":"publisher","DOI":"10.1038\/s41467-020-19649-1","volume":"11","author":"AD Nahmad","year":"2020","unstructured":"Nahmad, A. D. et al. Engineered B cells expressing an anti-HIV antibody enable memory retention, isotype switching and clonal expansion. Nat. Commun. 11, 5851 (2020).","journal-title":"Nat. Commun."},{"key":"1289_CR53","doi-asserted-by":"publisher","first-page":"998","DOI":"10.1038\/s41586-022-05216-9","volume":"609","author":"JH Lee","year":"2022","unstructured":"Lee, J. H. et al. Long-primed germinal centres with enduring affinity maturation and clonal migration. Nature 609, 998\u20131004 (2022).","journal-title":"Nature"},{"key":"1289_CR54","doi-asserted-by":"publisher","first-page":"131","DOI":"10.1016\/j.jim.2013.11.022","volume":"409","author":"M Sarzotti-Kelsoe","year":"2014","unstructured":"Sarzotti-Kelsoe, M. et al. Optimization and validation of the TZM-bl assay for standardized assessments of neutralizing antibodies against HIV-1. J. Immunol. Methods 409, 131\u2013146 (2014).","journal-title":"J. Immunol. Methods"},{"key":"1289_CR55","doi-asserted-by":"publisher","first-page":"6682","DOI":"10.1128\/JVI.75.14.6682-6686.2001","volume":"75","author":"P Zhu","year":"2001","unstructured":"Zhu, P., Olson, W. C. & Roux, K. H. Structural flexibility and functional valence of CD4-IgG2 (PRO 542): potential for cross-linking human immunodeficiency virus type 1 envelope spikes. J. Virol. 75, 6682\u20136686 (2001).","journal-title":"J. Virol."},{"key":"1289_CR56","unstructured":"Bailey C. C. Dandelions: B cell receptor sequence clustering and lineage graph generation. GitHub https:\/\/github.com\/baileych-bi\/dandelions (2024)."},{"key":"1289_CR57","unstructured":"Bailey C. C. dsa: Deep Sequencing Analysis. GitHub https:\/\/github.com\/baileych-bi\/dsa-win64 (2024)."}],"container-title":["Nature Biomedical Engineering"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41551-024-01289-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-024-01289-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41551-024-01289-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,12,24]],"date-time":"2024-12-24T13:03:13Z","timestamp":1735045393000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41551-024-01289-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,12,5]]},"references-count":57,"journal-issue":{"issue":"12","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["1289"],"URL":"https:\/\/doi.org\/10.1038\/s41551-024-01289-1","relation":{"has-preprint":[{"id-type":"doi","id":"10.1101\/2024.02.03.578630","asserted-by":"object"},{"id-type":"doi","id":"10.21203\/rs.3.rs-3922904\/v1","asserted-by":"object"}]},"ISSN":["2157-846X"],"issn-type":[{"value":"2157-846X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,12,5]]},"assertion":[{"value":"3 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 September 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 December 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"A.P., W.H., T.O., Y.Y. and M.F. are inventors of a patent describing the in vivo affinity maturation of antibodies and biologics. C.C.B., M.D.A. and M.F. have equity stakes in Emmune, Inc., which developed CD4-Ig-v0. The other authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}